

CONTAINS CONFIDENTIAL BUSINESS INFORMATION

**UNITED STATES INTERNATIONAL TRADE COMMISSION
WASHINGTON, D.C.
Before the Honorable Clark S. Cheney
Administrative Law Judge**

**In the Matter of
CERTAIN STRONTIUM-RUBIDIUM
RADIOISOTOPE INFUSION SYSTEMS,
AND COMPONENTS THEREOF
INCLUDING GENERATORS**

Investigation No. 337-TA-1110

CORRECTED EXPERT REPORT OF NORBERT J. PELC, Sc.D.
October 1, 2018

Oct 1, 2018
DATE



Norbert J. Pelc, Sc.D.

Table of Contents

I.	INTRODUCTION	1
II.	MY BACKGROUND, QUALIFICATIONS AND COMPENSATION	1
	A. Background and Qualifications.....	1
	B. Identification Of Expert Testimony In The Last Four Years.....	3
	C. Compensation	4
III.	LEGAL PRINCIPLES.....	4
	A. Perspective of a Person of Ordinary Skill in the Art	4
	B. Presumption of Validity	6
	C. Anticipation.....	6
	D. Written Description.....	7
	E. Non-Obviousness.....	8
	F. Assignor Estoppel	9
	G. Prosecution Laches	11
	H. Inventorship	12
IV.	PRIORITY DATE AND OVERVIEW OF THE ASSERTED PATENTS.....	13
	A. Priority Date.....	13
	B. Overview Of The Asserted Patents.....	14
V.	THE COMMISSION’S CLAIM CONSTRUCTION	17
VI.	RESPONDENTS ARE ESTOPPED FROM CHALLENGING THE VALIDITY AND ENFORCEABILITY OF THE ASSERTED PATENTS.....	18
VII.	THE ASSERTED PATENTS ARE NOT UNENFORCEABLE DUE TO PROSECUTION LACHES	22
	A. There Was No Unreasonable And Unexplained Delay	22
	1. ’467 Application	23
	2. ’200 Application	27
	3. ’484 Application	27
	4. ’320 Application	28
	B. There Was No Prejudice	29
VIII.	RESPONSE TO DR. STONE’S IMPROPER INVENTORSHIP ARGUMENT	31

CONTAINS CONFIDENTIAL BUSINESS INFORMATION

IX.	ANTICIPATION REBUTTAL	33
X.	THE ASSERTED PATENTS ARE NOT INVALID AS OBVIOUS	35
XI.	THE KLEIN THESIS, ALONE OR IN COMBINATION WITH OTHER REFERENCES, DOES NOT RENDER THE ASSERTED CLAIMS OF THE ASSERTED PATENTS OBVIOUS	38
A.	The Klein Thesis, Alone or in Combination with CardioGen-82, Tate, Medrad Intego, Akiyama, or Duchon, Does Not Render The Asserted Claims of the '826 Patent Obvious	39
1.	Independent Claim 1 of the '826 Patent	39
2.	Dependent Claim 2 of the '826 Patent	65
3.	Dependent Claim 3 of the '826 Patent	69
4.	Dependent Claim 5 of the '826 Patent	71
5.	Dependent Claim 9 of the '826 Patent	73
6.	Dependent Claim 10 of the '826 Patent	80
7.	Dependent Claim 11 of the '826 Patent	82
8.	Dependent Claim 12 of the '826 Patent	87
9.	Dependent Claim 13 of the '826 Patent	89
10.	Dependent Claim 14 of the '826 Patent	91
11.	Dependent Claim 17 of the '826 Patent	93
12.	Dependent Claim 18 of the '826 Patent	94
13.	Dependent Claim 19 of the '826 Patent	97
14.	Dependent Claim 28 of the '826 Patent	103
B.	The Klein Thesis, Alone or in Combination with CardioGen-82, Tate, Medrad Intego, Akiyama, or Duchon, Does Not Render The Asserted Claims of the '869 Patent Obvious	104
1.	Independent Claim 1 of the '869 Patent	104
2.	Dependent Claim 2 of the '869 Patent	126
3.	Dependent Claim 3 of the '869 Patent	128
4.	Dependent Claim 4 of the '869 Patent	130
5.	Dependent Claim 5 of the '869 Patent	132
6.	Dependent Claim 8 of the '869 Patent	133
7.	Dependent Claim 14 of the '869 Patent	133
8.	Dependent Claim 24 of the '869 Patent	135
9.	Dependent Claim 27 of the '869 Patent	142
10.	Dependent Claim 28 of the '869 Patent	144
11.	Dependent Claim 29 of the '869 Patent	147
12.	Dependent Claim 30 of the '869 Patent	149
C.	The Klein Thesis, Alone or in Combination with CardioGen-82, Tate, Medrad Intego, Akiyama, or Duchon, Does Not Render Obvious the Asserted Claims of the '870 Patent	151

CONTAINS CONFIDENTIAL BUSINESS INFORMATION

1.	Independent Claim 1 of the '870 Patent	151
2.	Dependent Claim 2 of the '870 Patent	165
3.	Dependent Claim 8 of the '870 Patent	168
4.	Dependent Claim 9 of the '870 Patent	175
5.	Dependent Claim 10 of the '870 Patent	177
6.	Dependent Claim 11 of the '870 Patent	180
7.	Dependent Claim 12 of the '870 Patent	182
8.	Dependent Claim 13 of the '870 Patent	184
9.	Dependent Claim 16 of the '870 Patent	186
10.	Dependent Claim 17 of the '870 Patent	186
11.	Dependent Claim 27 of the '870 Patent	189
XII.	THE CARDIOGEN-82 INFUSION SYSTEM, ALONE OR IN COMBINATION WITH OTHER REFERENCES, DOES NOT RENDER THE ASSERTED CLAIMS OF THE ASSERTED PATENTS OBVIOUS	191
A.	There Is No Motivation To Combine The Rubidium-82 Elution System Disclosed In CardioGen-82 And The Klein Thesis With The FDG Systems Disclosed In Tate And The Intego Operation Manual	191
B.	CardioGen-82, Alone or in Combination With The Klein Thesis, Tate, Intego Operations Manual, or Duchon, Does Not Render Obvious the Asserted Claims of the '826 Patent	193
1.	Independent Claim 1 of the '826 Patent	194
2.	Dependent Claim 2 of the '826 Patent	202
3.	Dependent Claim 3 of the '826 Patent	204
4.	Dependent Claim 5 of the '826 Patent	205
5.	Dependent Claim 9 of the '826 Patent	206
6.	Dependent Claim 10 of the '826 Patent	209
7.	Dependent Claim 11 of the '826 Patent	210
8.	Dependent Claim 12 of the '826 Patent	213
9.	Dependent Claim 13 of the '826 Patent	214
10.	Dependent Claim 14 of the '826 Patent	215
11.	Dependent Claim 17 of the '826 Patent	216
12.	Dependent Claim 18 of the '826 Patent	217
13.	Dependent Claim 19 of the '826 Patent	218
14.	Dependent Claim 28 of the '826 Patent	220
C.	CardioGen-82, Alone or in Combination With The Klein Thesis, Tate, Intego Operations Manual, or Duchon, Does Not Render Obvious the Asserted Claims of the '869 Patent	220
1.	Independent Claim 1 of the '869 Patent	222
2.	Dependent Claim 2 of the '869 Patent	234
3.	Dependent Claim 3 of the '869 Patent	235
4.	Dependent Claim 4 of the '869 Patent	236
5.	Dependent Claim 5 of the '869 Patent	238

CONTAINS CONFIDENTIAL BUSINESS INFORMATION

6.	Dependent Claim 8 of the '869 Patent.....	238
7.	Dependent Claim 14 of the '869 Patent.....	239
8.	Dependent Claim 24 of the '869 Patent.....	240
9.	Dependent Claim 27 of the '869 Patent.....	245
10.	Dependent Claim 28 of the '869 Patent.....	247
11.	Dependent Claim 29 of the '869 Patent.....	248
12.	Dependent Claim 30 of the '869 Patent.....	249
D.	CardioGen-82, Alone or in Combination With The Klein Thesis, Tate, Intego Operations Manual, or Duchon, Does Not Render Obvious the Asserted Claims of the '870 Patent	251
1.	Independent Claim 1 of the '870 Patent	252
2.	Dependent Claim 2 of the '870 Patent.....	259
3.	Dependent Claim 8 of the '870 Patent.....	260
4.	Dependent Claim 9 of the '870 Patent.....	263
5.	Dependent Claim 10 of the '870 Patent.....	264
6.	Dependent Claim 11 of the '870 Patent.....	265
7.	Dependent Claim 12 of the '870 Patent.....	266
8.	Dependent Claim 13 of the '870 Patent.....	268
9.	Dependent Claim 16 of the '870 Patent.....	268
10.	Dependent Claim 17 of the '870 Patent.....	269
11.	Dependent Claim 27 of the '870 Patent.....	271
XIII.	OBJECTIVE INDICIA OF NONOBVIOUSNESS.....	272
A.	There Was A Long Felt But Unmet Need	272
B.	Copying.....	276
C.	Failure Of Others	281
XIV.	CONCLUSION.....	283

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.